Orlando, FL-Among patients who undergo radiation treatment forprostate cancer following biochemical failure post-prostatectomy, use ofthe ProstaScint immunoscintigraphy scan appears to fail at reliably locatingdisease, researchers reported at the AUA annual meeting.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.